Pharmacology
DrugBankMechanism of Action
... JWH-018 is probably the most studied synthetic cannabinoid. It has been found in multiple preparations and has been shown to be a potent cannabinoid receptor (CB) agonist. CB1 is the principal receptor thought to be most highly responsible for the euphoria and psychoactive effects of THC. The CB2 receptor resides mostly in the immune system but has some effect on pain control and mood regulation. ...
Metabolism
... The high pharmacological and addictive potency of JWH-018 highlights the importance of elucidating the metabolism of JWH-018, without which a meaningful insight into its pharmacokinetics and its toxicity would not be possible. In the present study, the cytochrome P450 phase I metabolites of JWH-018 were investigated, after in vitro incubation of the drug with human liver microsomes, followed by liquid chromatography-tandem mass spectrometry analysis. This revealed monohydroxylation of the na
Receptor Profile
Receptor Actions
History & Culture
JWH-018 was synthesized by John W. Huffman, an organic chemist at Clemson University, as part of his research into compounds affecting the endocannabinoid system. The compound's designation derives from Huffman's initials.
2006–present
Beginning in 2006, products containing JWH-018 entered the grey market under the brand name Spice, sold as potpourri or incense and labeled "not for human consumption" to circumvent drug regulations. The brand expanded into a product family including Spice Gold, Spice Arctic Synergy, Spice Diamond, and Spice Tropical Synergy. On 15 December 2008, German pharmaceutical analysis identified JWH-018 as one of the active components in at least three versions of Spice products. The Spice brand became so influential that the term eventually came to be used generically to describe all synthetic cannabinoids, regardless of their specific chemical composition. Following regulatory bans, manufacturers demonstrated a pattern of circumventing controls through minor chemical modifications—analysis of products obtained four weeks after German prohibition found manufacturers had shortened the alkyl chain by one carbon atom to create technically distinct compounds.
Tolerance & Pharmacokinetics
drugs.wikiCross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 140 experience reports (106 Erowid + 34 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 27
Adverse Effects 66
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Heavy (n=12) |
|---|---|
| Visual Distortions | 58.3% |
| Anxiety | 41.7% |
| Confusion | 33.3% |
| Sedation | 33.3% |
| Hospital | 33.3% |
| Nausea | 33.3% |
| Euphoria | 33.3% |
| Music Enhancement | 33.3% |
| Memory Suppression | 25.0% |
| Color Enhancement | 16.7% |
| Stimulation | 16.7% |
| Muscle Tension | 16.7% |
| Tactile Enhancement | 16.7% |
| Auditory Effects | 16.7% |
| Introspection | 16.7% |
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 106 experience reports.
Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.
| Effect | Heavy (n=12) | |
|---|---|---|
| visual distortions | ||
| anxiety | ||
| confusion | ||
| sedation | ||
| hospital | ||
| nausea | ||
| euphoria | ||
| music enhancement | ||
| memory suppression | ||
| color enhancement | ||
| stimulation | ||
| muscle tension | ||
| tactile enhancement | ||
| auditory effects | ||
| introspection | ||
| dissociation |
Dosage Distribution
Dose distribution from experience reports
Real-World Dose Distribution
62K DosesFrom 56 individual dose entries
Smoked (n=29)
Oral (n=7)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Smoked
Oral
Redose Patterns
Redosing behavior across 80 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| United Kingdom | Controlled (Misuse of Drugs Act) | Classified under the Misuse of Drugs Act at the end of 2009. JWH-018 was among the first synthetic cannabinoids to be formally controlled in the UK, prompted by its widespread availability in products marketed as 'Spice' or herbal incense. |
| United States | Schedule I | Placed under federal control during the summer of 2012. Prior to scheduling, JWH-018 was sold openly in head shops and online under the guise of incense or potpourri labeled 'not for human consumption' to circumvent drug laws. |
Harm Reduction
drugs.wikiJWH‑018 is a full CB1 agonist with near-maximal efficacy (unlike Δ9‑THC’s partial agonism), yielding a much steeper dose‑response and a narrow safety margin—small increments can cause outsized effects. Blends sold as ‘Spice/K2’ are highly variable and often contain multiple or different noids than advertised; potency ‘hot‑spots’ and adulteration are common, so homogenization or volumetric preparation is safer than sprinkling on plant material. Inhalation peaks within minutes, making rapid redose tempting; wait ≥15 minutes between tiny measured inhalations to gauge effect and avoid panic reactions, vomiting, or syncope. Prominent toxicity signs include severe anxiety/agitation, tachycardia/hypertension, emesis, seizures, psychosis, and hyperthermia; seek urgent care for chest pain, persistent confusion, or any seizure. First-line ED care is supportive with benzodiazepines for agitation/seizures and active cooling/hydration; there is no specific antidote. Seizure risk appears higher with synthetic cannabinoids than with cannabis; combining with bupropion, tramadol, or stimulants adds further risk. Oral use has slower onset and a longer, less predictable course—common overdose pattern is early redose before the first dose peaks. Heavy cannabis tolerance does not protect against JWH‑018; tolerance builds rapidly, but cross‑tolerance is incomplete and does not prevent adverse reactions. Avoid driving and hazardous tasks for several hours after use; effects on coordination and judgment can persist beyond the perceived ‘high’. Pregnancy and lactation: cannabinoids cross the placenta and concentrate in breast milk; synthetic analog effects are poorly defined—avoid exposure. Routine reagent kits are not reliable for identifying specific noids; only accredited lab analysis can confirm identity/potency.
References
Data Sources
Cited References
- Atwood et al. (2010) - JWH-018 CB1 Potency
- Brents et al. (2011) - Phase I Metabolites Activity
- Every-Palmer (2011) - JWH-018 and Psychosis
- Freeman et al. (2013) - Stroke Association
- Grigoryev et al. (2022) - Psychotomimetic Effects Study
- Human Inhalation Pharmacokinetics (2–3 mg)
- JWH-018 Phase 1 Pilot Study
- Koller et al. (2022) - Cannabinoid-Induced Seizures
- PsychonautWiki: JWH-018
- Rat Tolerance and CB1 Desensitization
- Schneir et al. (2011) - Synthetic Cannabinoid Intoxication
- Schneir et al. (2012) - Convulsions Associated with Use
- Human inhalation PK (2–3 mg)
- Phase-1 pilot, 2 & 3 mg inhaled
- Psychotomimetic 5.5 mg study
- Rat tolerance & CB1 desensitisation
- Severe toxicity with seizures
- CYP2C9 polymorphism metabolism
Drugs.wiki References
- EUDA synthetic cannabinoids drug profile (background, variability, structural class)
- EUDA Joint Report table: JWH‑018 CB1 efficacy (full agonist; high Emax) and severe adverse events list
- Euro-DEN analysis: higher seizure odds with synthetic cannabinoids vs many drugs
- NCBI Bookshelf (CBHSQ/SAMHSA): synthetic cannabinoids cause severe agitation, seizures, psychosis; withdrawal can occur
- NCBI StatPearls: cannabinoid/synthetic cannabinoid toxicity and ED management (benzodiazepines first-line; supportive care)
- DrugBank review: JWH‑018 metabolism primarily via CYP1A2 and CYP2C9; UGT in secondary metabolism
- Erowid Spice product page: mislabeling, multiple actives, variability in herbal blends
- UNODC 2013 report (mirrored by Erowid): synthetic cannabinoids can raise blood pressure and cause myocardial ischemia
- Drugs-Forum wiki and threads: tolerance anecdotes; dosing pitfalls incl. ‘eyeballing’ risk; oral duration reports
- Drugs-Forum thread: oral JWH‑018 duration and effects example
- Drugs-Forum thread: ‘eyeballing’ warnings and mismeasurement risk
- EUDA 2025 NPS report: mis-selling of semi-synthetic/synthetic cannabinoids in cannabis products